Diarylhydantoin compounds

• US 7,709,517 B2
• Filed: 05/15/2006
• Issued: 05/04/2010
• Est. Priority Date: 05/13/2005
• Status: Active Grant

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Sawyers, Charles L., Chen, Charlie D., Welsbie, Derek, Wongvipat, John, Jung, Michael E., Tran, Chris, Ouk, Samedy, Yoo, Dongwon
• Primary Examiner(s): Shameem, Golam M
• Application Number:
  US11/433,829
• Publication Number:
  US 20070004753A1
• Time in Patent Office: 1,450 Days
• Field of Search: 548/300.1, 548/316.4, 548/317.1, 548/321.1, 514/385, 514/386, 514/392, 544/358, 544/359, 544/370, 546/184, 546/192, 546/207, 546/210
• US Class Current: 514/392
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 17/10 Anti-acne agents
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 233/70 One oxygen atom
• CPC Class Codes: C07D 233/74 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
• CPC Class Codes: C07D 233/86 Oxygen and sulfur atoms, e.g. thiohydantoin
• CPC Class Codes: C07D 235/02 condensed with carbocyclic rings or ring systems
• CPC Class Codes: C07D 471/10 Spiro-condensed systems

Abstract

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

Claims

1. A compound selected from the group consisting of

2. The compound of claim 1 having the formula

3. The compound of claim 1, having the formula

4. The compound of claim 1, having the formula

5. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

6. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 4, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

8. A pharmaceutical acceptable salt of a compound according to claim 1.

9. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt of a compound of claim 1, and a pharmaceutically acceptable carrier or diluent.

10. A pharmaceutical composition according to claim 9, wherein the compound is dissolved.

11. A pharmaceutical composition according to claim 9, comprising a solvent.

12. A pharmaceutical composition according to claim 9 comprising one or more of dimethylsulfoxide (DSMO), polyethylene glycol (PEG), and water.

13. A pharmaceutical composition according to claim 9, dimethylsulfoxide (DSMO), polyethylene glycol (PEG), and water.